Alzheimer’s disease (AD), a chronic degenerative illness that affects the mind and brain, is partially characterized by selective neuronal loss (AD kills brain cells) and cognitive deficits.
Generally speaking, scientists believe that AD originates in part from genetic, environmental, and lifestyle causes. Established risk factors include lack of exercise, obesity, hypertension, diabetes, depression, and smoking. More specifically, one hypothesis proposes beta-amyloid plaque as a factor, partially due to doctors observing higher concentrations in the brain cells of Alzheimer patients.
Another discovery in AD involves a protein called tau, which in AD tangles and twists, preventing the delivery of nutrients to brain cells. Scientists believe that these plaques and tangles induce neuro-chemical and inflammatory changes responsible for the development of the disease.
Rated 2.4 / 5 (How Ratings Work)
Possible to probable range of efficacy of cannabis for treatment of alzheimer's disease.
Based on 28 Studies from 1997 - 2017
Study Name, Description & Year
Rating
Cannabinoid Receptor 2 Signaling In Neurodegenerative Disorders: From Pathogenesis To A Promising Therapeutic Target
Review — 2017
Neurological Aspects Of Medical Use Of Cannabidiol
Review/Meta-Analysis — 2017
GPR3 And GPR6, Novel Molecular Targets For Cannabidiol
Laboratory Study — 2017
Safety And Efficacy Of Medical Cannabis Oil For Behavioral And Psychological Symptoms Of Dementia: An-Open Label, Add-On, Pilot Study
Human trial conducted on 11 patient with AD — 2016
ENDOCANNABINOID SYSTEM: A Multi-facet Therapeutic Target
Review — 2016
Amyloid Proteotoxicity Initiates An Inflammatory Response Blocked By Cannabinoids
Laboratory Study — 2016
Activity Of Muscarinic, Galanin And Cannabinoid Receptors In The Prodromal And Advanced Stages In The Triple Transgenic Mice Model Of Alzheimer's Disease
Animal study (mice) — 2016
Delineating The Efficacy Of A Cannabis-Based Medicine At Advanced Stages Of Dementia In A Murine Model.
Animal study (mice) — 2016
Endocannabionoid System In Neurological Disorders
Review — 2016
Cannabinoids In Late-onset Alzheimer's Disease
Review — 2015
Cannabinoids In Neurodegenerative Disorders And Stroke/Brain Trauma: From Preclinical Models To Clinical Applications
Review — 2015
β-Caryophyllene Ameliorates The Alzheimer-like Phenotype In APP/PS1 Mice Through CB2 Receptor Activation And The PPARγ Pathway.
Animal study (mice) — 2014
Cannabidiol As An Emergent Therapeutic Strategy For Lessening The Impact Of Inflammation On Oxidative Stress
Review — 2011
Cannabinoid Receptors And Endocannabinoids: Role In Neuroinflammatory And Neurodegenerative Disorders
Literature review — 2010
The Activation Of Cannabinoid CB2 Receptors Stimulates In Situ And In Vitro Beta-amyloid Removal By Human Macrophages
Laboratory — 2009
The Role Of The Endocannabinoid System In Alzheimer's Disease: Facts And Hypotheses
Meta-analysis and literature review — 2008
The Cannabinoid Receptor Agonist Nabilone For The Treatment Of Dementia-related Agitation
Human (1 patient) — 2008
Delta-9-tetrahydrocannabinol For Nighttime Agitation In Severe Dementia
A human trial conducted on six patients with dementia (5 with Alzheimer's and one with vascular dementia). — 2006
A Molecular Link Between The Active Component Of Marijuana And Alzheimer's Disease Pathology
Laboratory Study — 2006
Prevention Of Alzheimer's Disease Pathology By Cannabinoids: Neuroprotection Mediated By Blockade Of Microglial Activation
Rodent study — 2005
Neuroprotective Effect Of Cannabidiol, A Non-psychoactive Component From Cannabis Sativa, On Beta-amyloid-induced Toxicity In PC12 Cells
Laboratory Study — 2004
Cannabinoid CB2 Receptors And Fatty Acid Amide Hydrolase Are Selectively Overexpressed In Neuritic Plaque-associated Glia In Alzheimer's Disease Brains
Laboratory Study — 2003
Anandamide And Noladin Ether Prevent Neurotoxicity Of The Human Amyloid-beta Peptide
Laboratory Study — 2002
Effects Of Dronabinol On Anorexia And Disturbed Behavior In Patients With Alzheimer's Disease
A placebo-controlled crossover design conducted on 15 patients with probable Alzheimer's disease. — 1997